Collectively, aberrant alternative splicing of FGFR1–3 adds an additional layer of complexity to FGFR dysregulation in solid tumors, with implications for tumor biology, biomarker interpretation, and therapeutic targeting. This evidence concerns the gene FGFR1 and neoplasm.